VivoSeq
Other

Mavacamten

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Mavacamten is an early-stage landscape with 0 programs across 1 company. The most active players are Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed9 · 90%
Recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
Recruiting·—·N/A·NCT06023186·20 enrolled
A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT05362045·158 enrolled
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
Completed·LLianBio LLC·Phase 1·NCT05135871·45 enrolled
A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT06211179·34 enrolled
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2/3·NCT03723655·314 enrolled
A Study to Evaluate the Effects of Mavacamten in Healthy Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT05719805·84 enrolled
A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT05658146·95 enrolled
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT04349072·112 enrolled
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT04766892·30 enrolled
A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT05320094·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)